Nasdaq · CIK 0001582313
XENE Xenon Pharmaceuticals Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $36.44 on Oct 9, 2026, +1% from the 52-week low and -49% from the high.
Last 90 days
Net insider value
+$1.7M
more bought than sold
Buys
2
$1.7M by 2 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
XENEOct 9, 2026 · close 36.44
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Xenon Pharmaceuticals Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 75Notable | Thomas Patrick Kelly Chief Financial Officer buy | $560k 15,000 shares | - | +2% from low-48% from high | |
| 86Strong | Ian Mortimer PRESIDENT & CEO buy | $1.1M 30,000 shares | +151% | +2% from low-48% from high | |
| 15Weak | Steven Gannon director sell | $91 3 shares | -0% | +9% from low-33% from high | |
| 49Moderate | Sherry Aulin Chief Financial Officer sell | $771k 18,709 shares | -260% | - | |
| 17Weak | Gary Patou director sell | $201k 4,891 shares | -19% | - |
Transactions
The last 42 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Ian Mortimer PRESIDENT & CEO | POpen-market purchase Common Shares | +30,000 | $37.38 | $1.1M | 49,923 | 11 d ago |
| Sep 30, 2026 | Thomas Patrick Kelly Chief Financial Officer | POpen-market purchase Common Shares | +15,000 | $37.32 | $560k | 15,000 | 11 d ago |
| Sep 1, 2026 | Dawn Svoronos director | MOption exercise Common Shares | +5,144 | $8.15 | $42k | 31,373 | 39 d ago |
| Sep 1, 2026 | Dawn Svoronos director | MOption exercise Stock Option (Right to Buy)derivative | -5,144 | $0.00 | $0 | 0 | 39 d ago |
| Jun 23, 2025 | Darren S Cline Chief Commercial Officer | AGrant or award Share Option (Right to Buy)derivative | +185,800 | $0.00 | $0 | 185,800 | Jun 24, 2025 |
| Jun 5, 2025 | Justin D. Gover director | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | Dawn Svoronos director | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | Gary Patou director | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | Patrick Machado director | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | Elizabeth A. Garofalo director | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | Steven Gannon director | SOpen-market sale Common Shares | -3 | $30.48 | $91 | 7,141 | Jun 6, 2025 |
| Jun 5, 2025 | Gillian Cannon director | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | Elizabeth A. Garofalo director | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| Jun 5, 2025 | Steven Gannon director | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | Justin D. Gover director | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| Jun 5, 2025 | Patrick Machado director | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| Jun 5, 2025 | Gillian Cannon director | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| Jun 5, 2025 | Gary Patou director | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| Jun 5, 2025 | Dawn Svoronos director | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| Jun 5, 2025 | Steven Gannon director | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| May 14, 2025 | Steven Gannon director | MOption exercise Common Shares | +5,144 | $12.57 | $65k | 7,144 | May 16, 2025 |
| May 14, 2025 | Steven Gannon director | MOption exercise Stock Option (Right to Buy)derivative | -5,144 | $0.00 | $0 | 0 | May 16, 2025 |
| Mar 12, 2025 | Christopher John Kenney Chief Medical Officer | AGrant or award Share Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Mar 13, 2025 |
| Mar 12, 2025 | Andrea DiFabio Chief Legal Officer | AGrant or award Share Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Mar 13, 2025 |
| Mar 12, 2025 | Andrea DiFabio Chief Legal Officer | AGrant or award Restricted Share Unitsderivative | +15,000 | $0.00 | $0 | 15,000 | Mar 13, 2025 |
| Mar 12, 2025 | Christopher John Kenney Chief Medical Officer | AGrant or award Restricted Share Unitsderivative | +15,000 | $0.00 | $0 | 15,000 | Mar 13, 2025 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | MOption exercise Common Shares | +9,334 | $9.44 | $88k | 9,334 | Dec 19, 2024 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | FTax withholding Common Shares | -2,135 | $41.28 | $88k | 7,199 | Dec 19, 2024 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | SOpen-market sale Common Shares | -7,199 | $41.23 | $297k | 0 | Dec 19, 2024 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | MOption exercise Common Shares | +16,000 | $11.58 | $185k | 16,000 | Dec 19, 2024 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | FTax withholding Common Shares | -4,490 | $41.28 | $185k | 11,510 | Dec 19, 2024 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | SOpen-market sale Common Shares | -11,510 | $41.19 | $474k | 0 | Dec 19, 2024 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -9,334 | $0.00 | $0 | 0 | Dec 19, 2024 |
| Dec 18, 2024 | Sherry Aulin Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -16,000 | $0.00 | $0 | 6,000 | Dec 19, 2024 |
| Nov 22, 2024 | Gary Patou director | MOption exercise Common Shares | +3,500 | $7.38 | $26k | 27,073 | Nov 22, 2024 |
| Nov 22, 2024 | Gary Patou director | FTax withholding Common Shares | -649 | $39.80 | $26k | 26,424 | Nov 22, 2024 |
| Nov 22, 2024 | Gary Patou director | SOpen-market sale Common Shares | -2,851 | $41.11 | $117k | 23,573 | Nov 22, 2024 |
| Nov 22, 2024 | Gary Patou director | MOption exercise Common Shares | +3,086 | $13.48 | $42k | 26,659 | Nov 22, 2024 |
| Nov 22, 2024 | Gary Patou director | FTax withholding Common Shares | -1,046 | $39.80 | $42k | 25,613 | Nov 22, 2024 |
| Nov 22, 2024 | Gary Patou director | SOpen-market sale Common Shares | -2,040 | $41.05 | $84k | 23,573 | Nov 22, 2024 |
| Nov 22, 2024 | Gary Patou director | MOption exercise Stock Option (Right to Buy)derivative | -3,500 | $0.00 | $0 | 0 | Nov 22, 2024 |
| Nov 22, 2024 | Gary Patou director | MOption exercise Stock Option (Right to Buy)derivative | -3,086 | $0.00 | $0 | 0 | Nov 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sherry AulinChief Financial Officer
- Gillian Cannondirector
- Darren S ClineChief Commercial Officer
- Andrea DiFabioChief Legal Officer
- Steven Gannondirector
- Elizabeth A. Garofalodirector
- Justin D. Goverdirector
- Christopher John KenneyChief Medical Officer
- Thomas Patrick KellyChief Financial Officer
- Ian MortimerPRESIDENT & CEO
- Patrick Machadodirector
- Gary Patoudirector
- Dawn Svoronosdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.